IL-23 gene therapy for mouse bladder tumour cell lines

BJU International

Volumn 108, Issue 6, 2011, Pages 914-921

  Kuramoto, Tomomi ^a   Fujii, Reona ^a   Nagai, Hiroshi ^b   Belladonna, Maria Laura ^d   Yoshimoto, Takayuki ^c   Kohjimoto, Yasuo ^a   Inagaki, Takeshi ^a   Hara, Isao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

bladder; bladder carcinoma; gene therapy; interleukin 23; mice

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-23; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; URINARY BLADDER NEOPLASMS;

EID: 80052094819     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10025.x     Document Type: Article

References (30)

1. Cookson MS, Herr HW, Zhang ZF, Soloway ZF, Sogani S, Fair WR,. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7 (Pubitemid 27251595)
2. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG,. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990; 144: 641-5 (Pubitemid 20296710)
3. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L,. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 2008; 113: 710-6
4. Orsola A, Cecchini L, Raventos CX, et al,. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 2010; 105: 202-7
5. Morales A, Eidinger D, Bruce AW,. Intracavitary bacillus calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3
6. Morales A, Eidinger D,. Bacilllus Calmette-Guerin in the teatment of adenicarcinoma of the kidney. J Urol 1976; 115: 377-80
7. Oppmann B, Lesley R, Blom B, et al,. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-25
8. Pflanz S, Timans JC, Cheung J, et al,. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-90 (Pubitemid 34786477)
9. Dannull J, Su Z, Rizzieri D, et al,. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 151: 3623-33 (Pubitemid 43121851)
10. Wang YQ, Ugai S, Shimozato O, et al,. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003; 105: 820-4 (Pubitemid 36706106)
11. Lo CH, Lee SC, Wu PY, et al,. Antitumor and antimetastatic activity of IL-23. J Immunol 2003; 171: 600-7
12. Musiani P, Modesti A, Giovarelli M, et al,. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol Today 1997; 18: 32-6 (Pubitemid 27072431)
13. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN,. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 1995; 61: 253-60
14. Hara I, Hotta H, Sato N, Eto H, Arakawa S, Kamidono S,. Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin-2. Jpn J Cancer Res 1996; 87: 724-9 (Pubitemid 26261694)
15. Hara I, Nagai H, Miyake H, et al,. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 2000; 7: 83-90 (Pubitemid 30080991)
16. Hikosaka S, Hara I, Miyake H, Hara S, Kamidono S,. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol 2004; 11: 647-52 (Pubitemid 39128567)
17. Hara S, Nagai H, Miyake H, et al,. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 2001; 165: 2039-43
18. Furukawa J, Hara I, Nagai H, Yao A, Oniki S, Fujisawa M,. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 2006; 176: 1198-203 (Pubitemid 44142565)
19. Kumano M, Hara I, Furukawa J, et al,. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma. J Urol 2007; 178: 1504-9 (Pubitemid 47368380)
20. Belladonna ML, Renauld JC, Bianchi R, et al,. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002; 168: 5448-54 (Pubitemid 34556122)
21. Matsui M, Moriya O, Belladonna ML, et al,. Adjuvant Activities of Novel Cytokines, Interleukin-23(IL-23) and IL-27, for Induction oh Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A 0201 Transgenic Mice. J Virol 2004; 78: 9093-104 (Pubitemid 39096520)
22. Oniki S, Nagai H, Horikawa T, et al,. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006; 66: 6395-404
23. Sakaguchi S,. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52 (Pubitemid 41716771)
24. Fontenot JD, Rudensky AY,. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-7 (Pubitemid 41716769)
25. von Boehmer H,. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-44 (Pubitemid 41716770)
26. Curiel TJ, Coukos G, Zou L, et al,. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9 (Pubitemid 39273735)
27. Shimizu J, Yamazaki S,. Sakaguchi S Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-8
28. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E,. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-33 (Pubitemid 29316012)
29. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al,. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-32 (Pubitemid 32983017)
30. Comes A, Rosso O, Orengo AM, et al,. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006; 176: 1750-8 (Pubitemid 43134320)